Newer technology to control blood sugar works better than conventional methods

July 9, 2012

Newer technologies designed to help people with type 1 diabetes monitor their blood sugar levels daily work better than traditional methods and require fewer painful needle sticks, new Johns Hopkins research suggests.

The research findings, published online in the July 10 issue of the , suggest that even though these diabetic control technologies are more costly, people with diabetes who use an insulin pump are more satisfied with their treatment and quality of life than those who give themselves insulin shots many times a day.

Researchers say they still want to investigate how patients using these convenient technologies fare in the long term as compared to those who use older methods.

"Our study was designed to help patients and physicians better understand the effectiveness of insulin pumps and sensors that provide constant compared to conventional approaches," says the study's senior author, Sherita Hill Golden, M.D., M.H.S., an associate professor in the division of at the Johns Hopkins University School of Medicine. "We found that certain devices confer real benefits."

Diabetes is a condition marked by the inability of the body to properly manage the level of glucose (sugar) in the blood. In type 1 diabetes, the body does not make insulin, the hormone that regulates the body's use of sugar. Individuals with type 1 diabetes need insulin to keep even before and after meals and at all other times. People with the disorder must therefore monitor their frequently, usually by pricking their fingers many times a day to obtain blood and using a glucose monitor and test strips to detect blood sugar amounts.

Without strict control of glucose, diabetic individuals sustain serious and chronic complications, including blindness and tissue damage. Roughly 5 percent to 10 percent of people with diabetes have type 1, which used to be known as juvenile-onset diabetes.

In their study, Golden and her colleagues reviewed and re-analyzed data from 33 randomized controlled trials that compared the newer technologies to conventional methods of monitoring and controlling blood sugar levels. The new technologies they looked at were primarily real-time continuous glucose monitoring devices and insulin pumps.

The continuous monitoring devices track blood sugar levels all day and night, as often as every five minutes, using a sensor that is attached to the abdomen with a small needle held in place by tape. The sensor sends the results to a display that is worn on the belt. Diabetic individuals can make decisions about adjusting insulin therapy and/or activity levels based on the readouts. Patients still need to prick their fingers two to four times a day to make sure the device is working properly, but that is down from as many as eight to 10 times a day for patients trying to strictly control blood sugar. These devices also sound alarms if the blood sugar level is dangerously high or low.

The researchers found that children, teens and adults with type 1 diabetes who used continuous monitoring had lower blood glucose levels than those who used finger stick testing alone. They also spent less overall time with too much blood sugar (hyperglycemia). Both methods worked equally well to control hypoglycemia, the condition that results when blood sugar levels are too low.

Insulin pumps are small devices attached to a small tube and needle that goes under the skin in the belly area. The devices provide insulin around the clock, as needed. People with diabetes can either program the device with the push of a button based on finger stick glucose measurements or link the pump to the continuous monitor. The latter is called a "sensor-augmented pump."

While there was little difference in blood sugar control in those who give themselves multiple insulin shots a day versus those who used , those with who used the sensor-augmented pumps, pumps that include real-time continuous glucose monitoring devices, did much better controlling blood sugar than those who used finger stick testing and shots.

Since the new devices are more costly, Golden says it is important to make sure they are used by the patients who will get the most benefit from them.

"Those who use the devices as prescribed do the best at maintaining blood sugar control," she says. "Adherence is the key to effectiveness."

Golden says that not all insurance companies cover the new technologies. Medicare, for example, doesn't cover the real-time continuous glucose monitoring sensors. Golden says her study was unable to determine whether people over 65 benefit specifically from using the device.

Explore further: For diabetics not on insulin, self-monitoring blood sugar has no benefit

Related Stories

For diabetics not on insulin, self-monitoring blood sugar has no benefit

January 20, 2012
For type 2 diabetics who are not on insulin, monitoring their blood sugar does little to control blood sugar levels over time and may not be worth the effort or expense, according to a new evidence review.

Experimental insulin drug prevents low blood sugar

June 25, 2012
An experimental insulin drug prevented low blood sugar among diabetic patients more often than a popular drug on the market, a new study finds. The results will be presented at The Endocrine Society's 94th Annual Meeting ...

Diabetes: Tighter control of blood sugar prevents nerve condition, but at what risk?

June 12, 2012
Aggressive control of blood sugar levels in diabetes can help to prevent a painful condition affecting patients' nerves, according to a new systematic review in the Cochrane Library. However, the review suggests that optimal ...

Engineering new weapons in the fight against juvenile diabetes

June 6, 2011
Engineering researchers at Rensselaer Polytechnic Institute are combining automation techniques from oil refining and other diverse areas to help create a closed-loop artificial pancreas. The device will automatically monitor ...

Recommended for you

Drug found that induces apoptosis in myofibroblasts reducing fibrosis in scleroderma

December 15, 2017
(Medical Xpress)—An international team of researchers has found that the drug navitoclax can induce apoptosis (self-destruction) in myofibroblasts in mice, reducing the spread of fibrosis in scleroderma. In their paper ...

How defeating THOR could bring a hammer down on cancer

December 14, 2017
It turns out Thor, the Norse god of thunder and the Marvel superhero, has special powers when it comes to cancer too.

Researchers track muscle stem cell dynamics in response to injury and aging

December 14, 2017
A new study led by researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) describes the biology behind why muscle stem cells respond differently to aging or injury. The findings, published in Cell Stem Cell, ...

'Human chronobiome' study informs timing of drug delivery, precision medicine approaches

December 13, 2017
Symptoms and efficacy of medications—and indeed, many aspects of the human body itself—vary by time of day. Physicians tell patients to take their statins at bedtime because the related liver enzymes are more active during ...

Study confirms link between the number of older brothers and increased odds of being homosexual

December 12, 2017
Groundbreaking research led by a team from Brock University has further confirmed that sexual orientation for men is likely determined in the womb.

Potassium is critical to circadian rhythms in human red blood cells

December 12, 2017
An innovative new study from the University of Surrey and Cambridge's MRC Laboratory of Molecular Biology, published in the prestigious journal Nature Communications, has uncovered the secrets of the circadian rhythms in ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.